Form 4: Eledon Pharmaceuticals Director Acquires Stock Options and Restricted Stock Units

Eledon Pharmaceuticals director John S. McBride was granted stock options and restricted stock units on January 10, 2025.

Summary

• John S. McBride, a director at Eledon Pharmaceuticals, was granted stock options for 30,870 shares at an exercise price of $4.04 per share.
• These options vest 100% on January 10, 2026, and expire on January 10, 2035.
• McBride also received 3,430 restricted stock units (RSUs), each representing one share of common stock.
• These RSUs also vest 100% on January 10, 2026.
• Both the stock options and RSUs were granted on January 10, 2025.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation for a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options and RSUs to a director aligns their interests with the company's long-term success.
• The vesting schedule encourages the director's continued service and contribution to the company.

Industry Context

The granting of stock options and restricted stock units is a common practice in the pharmaceutical industry to incentivize and retain key personnel, particularly directors.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for director compensation across the biotechnology and pharmaceutical industries.
• Vesting schedules of one year are common, aligning with typical performance review cycles.
• The exercise price of $4.04 for the stock options is a typical market price at the time of grant.

Stakeholder Impact

• Shareholders may view the grant of equity to directors positively as it aligns their interests with the company's performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, director, Eledon Pharmaceuticals, equity compensation, vesting